References
- Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329)71–86
- Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: Theory and practice. Blood 1994; 83(4)885–898
- Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(3 Suppl.)234S–264S
- Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56(3)624–632
- Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72(8)3073–3076
- Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61(2)314–319
- Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Working Group on Aspirin Resistance. Aspirin resistance: Position paper of the working group on aspirin resistance. J Thromb Haemost 2005;3(6):1309–1311
- Bhatt DL. Aspirin resistance: More than just a laboratory curiosity. J Am Coll Cardiol 2004; 43(6)1127–1129
- Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006; 27(6)647–654
- Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2(1)15–28
- Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108(1)37–42
- Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46(6)986–993
- Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41(6)961–965
- Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43(6)1122–1126
- McGurk M, Dinsdale RC. A comparison of template bleeding time with mucosal petechiometry as a measure of the platelet function defect induced by aspirin. Br J Oral Maxillofac Surg 1991; 29(3)173–175
- Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28(14)1702–1708
- Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J Invasive Cardiol 2009; 21(4)172–178
- Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115(19)2490–2496